Malignant solid neoplasm, NTRK-mutated
Revision as of 00:48, 7 December 2018 by Warner-admin (talk | contribs) (Text replacement - "http://www.nejm.org" to "https://www.nejm.org")
2 regimens on this page
3 variants on this page
|
All lines of therapy
Larotrectinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Drilon et al. 2018 (LOXO-TRK-14001) | Phase 1 |
| Drilon et al. 2018 (SCOUT) | Phase I/II |
| Drilon et al. 2018 (NAVIGATE) | Phase II |
Note: these three trials are all reported in a single publication; the doses here are the FDA-recommended doses.
Chemotherapy
- Larotrectinib (Vitrakvi) as follows:
- Adults: 100 mg PO BID
- Pediatrics: 100 mg/m2 (maximum dose of 100 mg) PO BID
Continued indefinitely
References
- SCOUT; NAVIGATE: Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-739. link to original article contains protocol PubMed